ramatroban has been researched along with Arterial Occlusive Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altavilla, D; Campo, GM; Canale, P; Caputi, AP; Ioculano, M; Sardella, A; Squadrito, F; Squadrito, G; Urna, G | 1 |
| Andreassian, B; Bellucci, S; Groussin, H; Jaillet, N; Kedra, W; Molho-Sabatier, P; Tobelem, G | 1 |
1 trial(s) available for ramatroban and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Ex vivo inhibition of platelet aggregation in patients with severe limb arteriopathy treated with BAY U3405, a specific TX A2 receptor antagonist.
Topics: Adult; Aged; Arterial Occlusive Diseases; Carbazoles; Double-Blind Method; Extremities; Female; Hemodynamics; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Sulfonamides | 1994 |
1 other study(ies) available for ramatroban and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arterial Occlusive Diseases; Blood Pressure; Carbazoles; Macrophages; Male; Myocardial Depressant Factor; Peroxidase; Phagocytosis; Rats; Rats, Sprague-Dawley; Receptors, Thromboxane; Shock; Splanchnic Circulation; Sulfonamides; Survival Rate; Thromboxane A2; Thromboxane B2 | 1994 |